References
- Sander B, Campo E, Hsi ED. Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation. Virchows Arch. 2023;482(1):131–145. doi:10.1007/s00428-022-03460-y
- National Cancer Institute. SEER Cancer Stat Facts: chronic lymphocyticleukemia/small lymphocytic lymphoma Bethesda, MD. 2023 [cited 2023 July 31]. Available from: https://seer.cancer.gov/statfacts/html/cllsll.html
- Delgado J, Nadeu F, Colomer D, et al. Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. Haematologica. 2020;105(9):2205–2217.
- Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679–1705. doi:10.1002/ajh.26367
- Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760. doi:10.1182/blood-2017-09-806398
- Patel K, Pagel JM. Current and future treatment strategies in chronic lymphocytic leukemia. J Hematol Oncol. 2021;14(1):69. doi:10.1186/s13045-021-01054-w
- US Food and Drug Administration (FDA). FDA approves zanubrutinib for chronic lymphocytic leukemiaor small lymphocytic lymphoma 2023 [updated 2023 January 19; cited 2023 July 31]. Available from: https://www.fda. gov/drugs/resources-information-approved-drugs/ fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma#:∼:text=FDA%20approves%20zanubrutinib%20for%20chronic% 20lymphocytic%20leukemia%20or%20small%20lymphocytic%20lymphoma,-Share&text=On%20January%2019%2C%202023%2C%20 the,small%20lymphocytic%20lympho ma%20(SLL)
- AL-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188–1200. doi:10.1016/S1470-2045(20)30443-5
- Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437. doi:10.1056/NEJMoa1509388
- Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–1291. doi:10.1016/S0140-6736(20)30262-2
- Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031–1043. doi:10.1016/S1470-2045(22)00293-5
- Mato AR, Davids MS, Sharman J, et al. Recognizing unmet need in the era of targeted therapy for CLL/SLL: "what’s past is prologue" (shakespeare). Clin Cancer Res. 2022;28(4):603–608. doi:10.1158/1078-0432.CCR-21-1237
- Eyre TA, Hess LM, Sugihara T, et al. Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study. Leuk Lymphoma. 2023;64(5):1005–1016. doi:10.1080/10428194.2023.2190436
- Kabadi SM, Near A, Wada K, et al. Real-world treatment patterns, adverse events, resource use, and costs among commercially insured, younger patients with chronic lymphocytic leukemia in the USA: a retrospective cohort study. Adv Ther. 2020;37(7):3129–3148. doi:10.1007/s12325-020-01350-w
- Mato AR, Barrientos JC, Ghosh N, et al. Prognostic testing and treatment patterns in chronic lymphocytic leukemia in the era of novel targeted therapies: results from the informCLL registry. Clin Lymphoma Myeloma Leuk. 2020;20(3):174–183 e3. doi:10.1016/j.clml.2019.10.009
- Hurvitz S, Guerin A, Brammer M, et al. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting. The Oncologist. 2014;19(9):901–908. doi:10.1634/theoncologist.2014-0059
- Ramsey S, Henk HJ, Smith GL, et al. First-, second and third-line lung cancer treatment patterns and associated costs in a US healthcare claims database. Lung Cancer Manag. 2015;4(3):131–143. doi:10.2217/lmt.15.12
- Seal BS, Sullivan SD, Ramsey S, et al. Medical costs associated with use of systemic therapy in adults with colorectal cancer. J Manag Care Pharm. 2013;19(6):461–467. doi:10.18553/jmcp.2013.19.6.461
- Wong W, Yim YM, Kim A, et al. Assessment of costs associated with adverse events in patients with cancer. PLoS One. 2018;13(4):e0196007. doi:10.1371/journal.pone.0196007
- Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120. doi:10.1056/NEJMoa1713976
- Mato AR, Ghosh N, Sharman JP, et al. Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry. Blood Adv. 2023;7(17):4760–4764. doi:10.1182/bloodadvances.2022008068
- US Food and Drug Administration (FDA). FDA approves venetoclax for CLL or SLL, with or without 17 p deletion, after one prior therapy 2018 [updated 2018 June 8; cited 2023 September 12]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-venetoclax-cll-or-sll-or-without-17-p-deletion-after-one-prior-therapy#:∼:text=On%20June%208%2C%202018%2C%20the,at%20least%20one%20prior%20therapy
- US Food and Drug Administration (FDA). Project Orbis: FDA approves acalabrutinib for CLL and SLL 2019 [updated 2019 November 21; cited 2023 September 12]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/project-orbis-fda-approves-acalabrutinib-cll-and-sll
- Woyach JA. Management of relapsed/refractory chronic lymphocytic leukemia. Am J Hematol. 2022;97 Suppl 2(Suppl 2):S11–S18. doi:10.1002/ajh.26683
- Hardy-Abeloos C, Pinotti R, Gabrilove J. Ibrutinib dose modifications in the management of CLL. J Hematol Oncol. 2020;13(1):66. doi:10.1186/s13045-020-00870-w
- O'Brien SM, Brown JR, Byrd JC, et al. Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol. 2021;11:720704. doi:10.3389/fonc.2021.720704
- Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133(12):1298–1307. doi:10.1182/blood-2018-11-846808
- Parikh SA, Achenbach SJ, Call TG, et al. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Med. 2020;9(10):3390–3399. doi:10.1002/cam4.2998
- UK CLL Forum. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016;101(12):1563–1572. doi:10.3324/haematol.2016.147900
- Williams AM, Baran AM, Casulo C, et al. Ibrutinib dose adherence and therapeutic efficacy in non-Hodgkin lymphoma: a single-center experience. Clin Lymphoma Myeloma Leuk. 2019;19(1):41–47. doi:10.1016/j.clml.2018.10.005
- Jacobs R, Wang R, He J, et al. Real world treatment patterns in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma switching from first line ibrutinib to acalabrutinib. Blood. 2022;140(Supplement 1):8017–8018. doi:10.1182/blood-2022-168081
- Sturm I, Oertel J, Oertel S, et al. Successful long-term monotherapy with rituximab in a patient with chronic lymphocytic leukemia of the B-cell-lineage: a case report. J Med Case Rep. 2008;2:275.
- Salles G, Barrett M, Foà R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232–2273. doi:10.1007/s12325-017-0612-x
- Murakhovskaya I. Rituximab use in warm and cold autoimmune hemolytic anemia. J Clin Med. 2020;9(12):4034. doi:10.3390/jcm9124034
- Mato AR, Hess LM, Chen Y, et al. Outcomes for patients with chronic lymphocytic leukemia (CLL) previously treated with both a covalent BTK and BCL2 inhibitor in the United States: a real-world database study. Clin Lymphoma Myeloma Leuk. 2023;23(1):57–67. doi:10.1016/j.clml.2022.09.007
- Lin VS, Lew TE, Handunnetti SM, et al. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood. 2020;135(25):2266–2270. doi:10.1182/blood.2020004782
- Mato AR, Hill BT, Lamanna N, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol. 2017;28(5):1050–1056. doi:10.1093/annonc/mdx031
- Mato AR, Roeker LE, Jacobs R, et al. Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy. Clin Cancer Res. 2020;26(14):3589–3596. doi:10.1158/1078-0432.CCR-19-3815